Literature DB >> 16365627

[Systemic lupus erythematosus presenting with a choreo-athetosic syndrome associated with antiphospholipid antibodies].

M A Rafai1, B El Moutawakil, I Gam, K Hakim, H Fadel, N Kissani, I Slassi.   

Abstract

INTRODUCTION: Chorea is a rare manifestation of systemic lupus erythematosus (1-4 percent), commonly affecting young woman. Chorea is revealing lupic disease in 50 percent, in the other cases it occurs early in the course of the disease. OBSERVATION: A 33-year-old woman was hospitalized for choreo-athetosic movements prevailing on the left leg and arm accompanied by behavioral and general state deterioration. The biological assessment consolidated the diagnosis of lupic disease associated antiphospholipides antibody (aPL). Cerebral magnetic resonance imaging (MRI) was normal except for cortical and subcortical atrophy. The patient was treated by corticosteroids (1mg/kg/day) and then was lost to follow-up.
CONCLUSION: We review data in the literature on the pathophysiological mechanisms of lupic chorea focusing particularly on role of aPL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16365627     DOI: 10.1016/s0035-3787(05)85161-6

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  3 in total

1.  Hemichorea with antiphospholipid antibodies in a patient with systemic lupus erythematosus.

Authors:  Ana Vide Brochado; Sofia Pimenta; Marta Silva; Raquel Sousa; Maria Manuel Campos; Iva Brito
Journal:  BMJ Case Rep       Date:  2009-08-19

Review 2.  Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome.

Authors:  José Fidel Baizabal-Carvallo; Cecilia Bonnet; Joseph Jankovic
Journal:  J Neural Transm (Vienna)       Date:  2013-04-13       Impact factor: 3.575

3.  Efficacy of intravenous immunoglobulin treatment in lupus erythematosus chorea.

Authors:  I Lazurova; Z Macejova; K Benhatchi; M Oetterová; E Antolová; R A Asherson; J Rovensky
Journal:  Clin Rheumatol       Date:  2007-05-09       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.